Roche Holdings Ltd ADR (RHHBY)

$45.52 +0.09 (0.20%)
Market Cap 289.08B
Revenue (ttm) 70.87B
Net Income (ttm) 9.40B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 14.62
Profit Margin 13.27%
Debt to Equity Ratio 0.96
Volume 1,861,100
Avg Vol 1,566,892
Day's Range N/A - N/A
Shares Out 6.36B
Stochastic %K 92%
Beta 0.45
Analysts Sell
Price Target $44.88

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
biolover
biolover Nov. 13 at 9:26 PM
$VKTX $ZEAL is one of the most overrated, obesity, or biotech companies. Survodutide has nasty toxicity with little efficacy and will not make it in the USA Its Amylin agonist has lowest efficacy among all Amylins. Company has 28 wk data now ( primary end point) and decides to withhold it I am surprised by $RHHBY deal with zeal. They are giving them 50% of combined CT388 revenue. Either this drug is so bad and they needed zeal amylin combination to save it, or Roche management is incompetent
7 · Reply
Cynatheris_804
Cynatheris_804 Nov. 13 at 8:46 PM
$RHHBY NXXT candle bodies thick, sellers losing control 🟩
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Nov. 13 at 7:44 PM
$RHHBY
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 13 at 7:36 PM
$SLS Share Price manipulation, ahead of the GPs Top Line Phase 3 Results, is offering a true Once in a Lifetime Investment Opportunity. $229M Manipulated Market Cap - worth $25B to Big Pharma the Instant the Phase 3 Results are Announced. Up to155 Institutional Funds Now Invested / up from just 39 when the IDMC UNBLINDED ACTUAL PHASE 3 INTERIM MOS AND IR DATA. Also, the Market Cap Increased 310% in Value from $77M to $220M Now -- since the IDMC INTERIM DATA was Unblinded. Also, sitting on $73.4M in CASH vs just $13.8M - when the IDMC .... ... AZA/VEN FAILED 3 Phase 3 AML Trials. -- You know $ABBV / $BMY $RHHBY Know Aza VEN are NOT the Reason We are Seeing Miraculous ALL Pooled MOS data...
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 13 at 3:17 PM
$SLS Up to 154 Institutional Funds Now Invested / up from just 39 when the IDMC UNBLINDED ACTUAL PHASE 3 INTERIM MOS AND IR DATA. Also, the Market Cap Increased 310% in Value from $77M to $220M Now -- since the IDMC INTERIM DATA was Unblinded. Also, sitting on $73.4M in CASH vs just $13.8M - when the IDMC .... ... AZA/VEN FAILED 3 Phase 3 AML Trials. -- You know $ABBV / $BMY $RHHBY Know Aza VEN are NOT the Reason We are Seeing Miraculous ALL Pooled MOS data... - Share Price manipulation, ahead of the GPs Top Line Phase 3 Results, is offering a true Once in a Lifetime Investment Opportunity. $229M Manipulated Market Cap - worth $25B to Big Pharma the Instant the Phase 3 Results are Announced.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 13 at 1:58 AM
$SLS @MarcoFla99 do you know what the "EX" in the (ex 13f/g ) means ??? it means EXCLUDING .. you also have to ADD the 13D/G/F Volume... got to be Closer to 50%. 153 Institutional Funds Now Invested / up from just 39 when the IDMC UNBLINDED ACTUAL PHASE 3 INTERIM MOS AND IR DATA Also, the Market Cap Increased from $77M to $220M Now, up 310% in Value since the IDMC INTERIM DATA was unblinded. Also, sitting on $73.4M in CASH vs just $13.8M - when the IDMC .... AZA/VEN FAILED 3 Phase 3 AML Trials. -- You know $ABBV / $BMY $RHHBY Know Aza VEN are NOT the Reason We are Seeing Miraculous ALL Pooled MOS data...
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 12 at 10:12 PM
$SLS @MarcoFla99 do you know what the (ex 13f/g ) means it means EXCLUDING .. you have to ADD the 13D/G/F Volume... gotto be Closer to 50%. 152 Institutional Funds Now Invested / up from just 39 when the IDMC UNBLINDED ACTUAL PHASE 3 INTERIM MOS AND IR DATA Also, the Market Cap Increased from $77M to $220M Now, up 310% in Value since the IDMC INTERIM DATA was unblinded. Also, sitting on $73.4M in CASH vs just $13.8M - when the IDMC .... AZA/VEN FAILED 3 Phase 3 AML Trials. -- You know $ABBV / $BMY $RHHBY Know Aza VEN are NOT the Reason We are Seeing Miraculous ALL Pooled MOS data...
1 · Reply
victoria_bell14
victoria_bell14 Nov. 12 at 7:28 PM
$RHHBY NXXT magnet at 2 getting stronger each test
0 · Reply
financiern
financiern Nov. 12 at 7:04 PM
$TGTX $RHHBY sure if they could do this, but Roche would be smart to divest Ocrevus off to a generic company and just straight buyout tgtx. They have all the reps already in the field. Synergies would be immediate… Thoughts?
3 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 12 at 6:36 PM
$SLS $ABBV and $RHHBY wanted Aza+VEN to Be a Cash Cow for AML Remission Maintenance - Extended 5 year Plus dosing- that is why they conducted the VIALE-M - Phase 3 Trial This is the Original SAP ... with Clearly Defined EFFICACY ENDPOINTs --- and it Failed ... @cea is lying again. Ps GPS is the Cash Cow. https://cdn.clinicaltrials.gov/large-docs/20/NCT04102020/SAP_001.pdf
0 · Reply
Latest News on RHHBY
No data available.
biolover
biolover Nov. 13 at 9:26 PM
$VKTX $ZEAL is one of the most overrated, obesity, or biotech companies. Survodutide has nasty toxicity with little efficacy and will not make it in the USA Its Amylin agonist has lowest efficacy among all Amylins. Company has 28 wk data now ( primary end point) and decides to withhold it I am surprised by $RHHBY deal with zeal. They are giving them 50% of combined CT388 revenue. Either this drug is so bad and they needed zeal amylin combination to save it, or Roche management is incompetent
7 · Reply
Cynatheris_804
Cynatheris_804 Nov. 13 at 8:46 PM
$RHHBY NXXT candle bodies thick, sellers losing control 🟩
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Nov. 13 at 7:44 PM
$RHHBY
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 13 at 7:36 PM
$SLS Share Price manipulation, ahead of the GPs Top Line Phase 3 Results, is offering a true Once in a Lifetime Investment Opportunity. $229M Manipulated Market Cap - worth $25B to Big Pharma the Instant the Phase 3 Results are Announced. Up to155 Institutional Funds Now Invested / up from just 39 when the IDMC UNBLINDED ACTUAL PHASE 3 INTERIM MOS AND IR DATA. Also, the Market Cap Increased 310% in Value from $77M to $220M Now -- since the IDMC INTERIM DATA was Unblinded. Also, sitting on $73.4M in CASH vs just $13.8M - when the IDMC .... ... AZA/VEN FAILED 3 Phase 3 AML Trials. -- You know $ABBV / $BMY $RHHBY Know Aza VEN are NOT the Reason We are Seeing Miraculous ALL Pooled MOS data...
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 13 at 3:17 PM
$SLS Up to 154 Institutional Funds Now Invested / up from just 39 when the IDMC UNBLINDED ACTUAL PHASE 3 INTERIM MOS AND IR DATA. Also, the Market Cap Increased 310% in Value from $77M to $220M Now -- since the IDMC INTERIM DATA was Unblinded. Also, sitting on $73.4M in CASH vs just $13.8M - when the IDMC .... ... AZA/VEN FAILED 3 Phase 3 AML Trials. -- You know $ABBV / $BMY $RHHBY Know Aza VEN are NOT the Reason We are Seeing Miraculous ALL Pooled MOS data... - Share Price manipulation, ahead of the GPs Top Line Phase 3 Results, is offering a true Once in a Lifetime Investment Opportunity. $229M Manipulated Market Cap - worth $25B to Big Pharma the Instant the Phase 3 Results are Announced.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 13 at 1:58 AM
$SLS @MarcoFla99 do you know what the "EX" in the (ex 13f/g ) means ??? it means EXCLUDING .. you also have to ADD the 13D/G/F Volume... got to be Closer to 50%. 153 Institutional Funds Now Invested / up from just 39 when the IDMC UNBLINDED ACTUAL PHASE 3 INTERIM MOS AND IR DATA Also, the Market Cap Increased from $77M to $220M Now, up 310% in Value since the IDMC INTERIM DATA was unblinded. Also, sitting on $73.4M in CASH vs just $13.8M - when the IDMC .... AZA/VEN FAILED 3 Phase 3 AML Trials. -- You know $ABBV / $BMY $RHHBY Know Aza VEN are NOT the Reason We are Seeing Miraculous ALL Pooled MOS data...
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 12 at 10:12 PM
$SLS @MarcoFla99 do you know what the (ex 13f/g ) means it means EXCLUDING .. you have to ADD the 13D/G/F Volume... gotto be Closer to 50%. 152 Institutional Funds Now Invested / up from just 39 when the IDMC UNBLINDED ACTUAL PHASE 3 INTERIM MOS AND IR DATA Also, the Market Cap Increased from $77M to $220M Now, up 310% in Value since the IDMC INTERIM DATA was unblinded. Also, sitting on $73.4M in CASH vs just $13.8M - when the IDMC .... AZA/VEN FAILED 3 Phase 3 AML Trials. -- You know $ABBV / $BMY $RHHBY Know Aza VEN are NOT the Reason We are Seeing Miraculous ALL Pooled MOS data...
1 · Reply
victoria_bell14
victoria_bell14 Nov. 12 at 7:28 PM
$RHHBY NXXT magnet at 2 getting stronger each test
0 · Reply
financiern
financiern Nov. 12 at 7:04 PM
$TGTX $RHHBY sure if they could do this, but Roche would be smart to divest Ocrevus off to a generic company and just straight buyout tgtx. They have all the reps already in the field. Synergies would be immediate… Thoughts?
3 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 12 at 6:36 PM
$SLS $ABBV and $RHHBY wanted Aza+VEN to Be a Cash Cow for AML Remission Maintenance - Extended 5 year Plus dosing- that is why they conducted the VIALE-M - Phase 3 Trial This is the Original SAP ... with Clearly Defined EFFICACY ENDPOINTs --- and it Failed ... @cea is lying again. Ps GPS is the Cash Cow. https://cdn.clinicaltrials.gov/large-docs/20/NCT04102020/SAP_001.pdf
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 12 at 5:58 PM
$SLS $ABBV $RHHBY PSA: @New_to_stocks aka @SLS_4Life aka @FlockofTURDS is LYING ABOUT THE VIALE Trials for Good Reason. - VIALE-M, a Large Phase 3 Trial for AML First Remission Maintenance / CR 1 Maintenance was TERMINATED due to Toxicity originally expected to enroll 360 Patients/ closed out at 112 and RESULTS WERE POSTED 8/20. Heavy Duty Toxicity in the all Oral combination of Aza+VEN - Even with Multiple Dosing REDUCTIONS, allowed, STILL toxic. AzaVEN is BAT for the REGAL P3 Control ARM REGAL a AML Second REMISSION Maintenance Trial CR2 VIALE-M is as Close to a comp there is ... and it FAILED https://clinicaltrials.gov/study/NCT04102020?term=viale-m&rank=9&tab=table&a=70&b=71&compareMode=sideBySide
1 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Nov. 11 at 2:26 PM
$LMDX $RHHBY Me? I think it's clear that Roche knew we would recover from moving too heavily into COVID. Roche knew other companies knew this as well, and would pay us closer to fair value. So while things looked bleak, they robbed our tech and duct taped the mouth of the CMA.
0 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Nov. 11 at 2:04 PM
$LMDX $RHHBY What else did the CMA say? WE STILL DON'T KNOW. Because it's heavily redacted. What did Roche need hidden? What did BioPharma need hidden?
0 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Nov. 11 at 1:54 PM
$LMDX $RHHBY Remember, folks. CMA not only said there were other interested parties but ALSO that we could have been profitable again without a sale at all. Then BioPharma flexed its muscle and forced the sale to Roche for cheap down our throats.
1 · Reply
biolover
biolover Nov. 10 at 6:04 PM
$VKTX because these analysts and journalists that tout the oral route know more than $ABBV $RHHBY $AMGN and others that are going purely for injectables 😂
1 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Nov. 10 at 2:12 PM
$LMDX $RHHBY Or D: All of the Above lol
0 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Nov. 10 at 1:32 PM
$LMDX $RHHBY
0 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Nov. 10 at 1:31 PM
$LMDX $RHHBY So the company we bought shares in is gone, and was worth 350m "lol" but the subsidiary (of the company we owned) that we did not own was worth a billion dollars, was purchased by Roche shares and all and is still active AS LumiraDX UK? ......
0 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Nov. 10 at 1:27 PM
$LMDX $RHHBY They made this as confusing as possible to conceal their actions and the money flow. LumiraDX UK ltd IS a subsidiary of the company we bought shares in. Yes, I said IS, because despite being bought by Roche, it's still active as Lumira. Sup with that?
1 · Reply
Quantumup
Quantumup Nov. 10 at 12:50 PM
Piper Sandler⬆️the PT on $CTMX to $6.5 from $5, reiterated at an Overweight rating, and said, 'Encouraging CX-801 Data @ SITC, More CX-2051 Data in 1Q:26' $MRK $RHHBY Piper Sandler added:
1 · Reply
dogDazeSummer
dogDazeSummer Nov. 10 at 10:59 AM
$IFRX Nice to see pre market volume holding average weighted pricing around $1.70 ~ ($1.6-$2) The more notional volume at higher levels helps not only liquidity but creates technical attraction from investors we never expected. We still need “investable data”- (data a phara can see getting FDA approved via efficacy/ MOA /safety) on 1 of the 3 options. As Niels has said, entities are under NDA & have been looking at various aspects. Some PG, HS, CSU maybe all. Those NDA’s expire the very second the data drops in next 90 minutes ——and “they” likely have a plan. Ex: buy (or sell) as much as we can up to $1.75, $2, $2.5 etc Defining “they:” 1. Existing institutional shareholders; likely to add on good data 2. New institutional bio / non bio funds; 3. Entities like $ABBV $AMGN $BIIB $RHHBY 4. Retail like us who have been waiting and are the largest subset of 1-4, ~75%
1 · Reply
DmcMouse
DmcMouse Nov. 9 at 12:37 PM
$LMDX That, This, no that. There so many twists and turns! What the heck is going on? $RHHBY Do the right things and take care of us shareholders.
0 · Reply